Atria Investments LLC increased its position in shares of Allergan PLC. (NYSE:AGN) by 5.2% during the second quarter, Holdings Channel reports. The fund owned 7,690 shares of the company’s stock after buying an additional 380 shares during the period. Atria Investments LLC’s holdings in Allergan PLC. were worth $1,869,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the stock. Veritas Asset Management LLP purchased a new position in shares of Allergan PLC. during the first quarter valued at about $761,339,000. Edgewood Management LLC boosted its position in shares of Allergan PLC. by 7.0% in the first quarter. Edgewood Management LLC now owns 2,704,211 shares of the company’s stock valued at $646,090,000 after buying an additional 178,055 shares during the last quarter. Epoch Investment Partners Inc. boosted its position in shares of Allergan PLC. by 3.8% in the first quarter. Epoch Investment Partners Inc. now owns 2,013,415 shares of the company’s stock valued at $481,045,000 after buying an additional 73,081 shares during the last quarter. UBS Asset Management Americas Inc. boosted its position in shares of Allergan PLC. by 0.3% in the first quarter. UBS Asset Management Americas Inc. now owns 1,995,281 shares of the company’s stock valued at $476,713,000 after buying an additional 5,042 shares during the last quarter. Finally, Blue Ridge Capital L.L.C. boosted its position in shares of Allergan PLC. by 24.1% in the first quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock valued at $456,313,000 after buying an additional 370,400 shares during the last quarter. 83.63% of the stock is currently owned by institutional investors.

Shares of Allergan PLC. (NYSE AGN) traded down 0.47% during midday trading on Wednesday, reaching $229.35. The company’s stock had a trading volume of 1,688,171 shares. The firm’s 50 day moving average is $245.03 and its 200 day moving average is $238.77. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80. The firm has a market capitalization of $76.67 billion, a price-to-earnings ratio of 6.99 and a beta of 1.16.

Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The company had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. During the same period last year, the company posted $3.35 earnings per share. The firm’s revenue was up 8.8% compared to the same quarter last year. Equities analysts forecast that Allergan PLC. will post $16.27 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be given a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 1.21%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.

TRADEMARK VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/atria-investments-llc-buys-380-shares-of-allergan-plc-agn-2/1496277.html.

AGN has been the subject of several research analyst reports. Zacks Investment Research upgraded Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 price objective for the company in a research note on Tuesday, July 11th. Goldman Sachs Group, Inc. (The) cut Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price target for the company. in a research report on Wednesday, May 10th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Allergan PLC. in a research report on Thursday, May 25th. Royal Bank Of Canada lifted their price target on Allergan PLC. from $279.00 to $284.00 and gave the company an “outperform” rating in a research report on Wednesday, May 10th. Finally, Deutsche Bank AG reiterated a “buy” rating and set a $273.00 price target (up from $265.00) on shares of Allergan PLC. in a research report on Monday, July 17th. Eight analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $275.49.

In other Allergan PLC. news, Director Nesli Basgoz sold 1,889 shares of the firm’s stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.36% of the company’s stock.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.